Funded in part by Eli Lilly and Company, Pfizer, Sanofi, Pharmavite, Meat and Livestock Australia, Servier, DSM, DSM Nutritional Products, Cilag
International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder
Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su KP
Psychotherapy and psychosomatics · 133 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Systematic review (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Nonprofit
- Wilson Foundation
- Company
- Eli Lilly and Company
- Company
- Pfizer
- Company
- Sanofi
- University or hospital
- Massachusetts General Hospital
- Company
- Pharmavite
- Nonprofit
- Geelong Region Medical Research Foundation
- Nonprofit
- National Alliance for Research on Schizophrenia and Depression
- Nonprofit
- David and Elaine Potter Foundation
- Nonprofit
- Australian Rotary Health
- Nonprofit
- Ian Potter Foundation
- Industry group
- Meat and Livestock Australia
- University or hospital
- University of Melbourne
- Government
- Ministry of Science and Technology, Taiwan
- Government
- National Health Research Institutes
- University or hospital
- China Medical University
- Company
- Servier
- University or hospital
- China Medical University, Taiwan
- Nonprofit
- Fernwood Foundation
- Company
- DSM
- Government
- National Institutes of Health
- Government
- Medical Research Council
- Government
- National Health and Medical Research Council
- Government
- Japan Society for the Promotion of Science
- University or hospital
- Brain and Behaviour Research Institute, University of Wollongong
- Company
- DSM Nutritional Products
- Government
- National Institute of Mental Health
- Government
- Division of Materials Research
- Company
- Cilag
- Grants
- National Health Research Institutes (DMR-107-091); Ministry of Science and Technology, Taiwan (NHRI-EX106-10528NI); National Health Research Institutes (CRS-108-048); China Medical University, Taiwan (CRS - 108-048); University of Melbourne (1108125); National Health Research Institutes (NHRI-EX106-10528NI); China Medical University, Taiwan (DMR-107-091); Ministry of Science and Technology, Taiwan (105-2918-I-039-001;); China Medical University, Taiwan (DMR-107-202); China Medical University, Taiwan (CRS-106-063); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-035); China Medical University, Taiwan (DMR-107-204); National Health Research Institutes (CRS-106-063); Ministry of Science and Technology, Taiwan (MOST 107?); National Health Research Institutes (DMR-107-204); National Health Research Institutes (CRS-106-063, DMR-107-202); Japan Society for the Promotion of Science (17H04253); Ministry of Science and Technology, Taiwan (MOST106-2314-B038-049); National Health Research Institutes (DRM-107-097); Ministry of Science and Technology, Taiwan (MOST 108-); Ministry of Science and Technology, Taiwan (MOST108-2320-B039-048); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-027-MY3); Ministry of Science and Technology, Taiwan (MOST108-2314-B039-016); National Health Research Institutes (EX106); National Health Research Institutes (DMR-107-202); China Medical University, Taiwan (DRM-107-097); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-031); National Health and Medical Research Council (1108125)
Based on 29 listed funder(s).
Publication
- Published
- 2019-01-01 · Psychother Psychosom · vol. 88 · issue 5 · pp. 263–273
- Publisher
- Karger Publishers
- Cited
- 199 citations · more than 99% of similar papers · 13.3× the field average
- Impact
- Top 10% most cited in its field
- References
- 85 works
- Access
- Free to read
- Research areas
- Alcoholism and Thiamine Deficiency · Diet and metabolism studies · Tryptophan and brain disorders
- Keywords
- Major depressive disorder, Guideline, Medicine, Psychiatry, Psychopathology, Eicosapentaenoic acid, Polyunsaturated fatty acid, Mood, Fatty acid
- MeSH
- humans, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, antidepressive agents, pregnancy, aged, child, societies, medical, female, biomarkers, major depressive disorder
15 authors
From TW, US, AU, JP, TH, IL, GB
- Ta‐Wei GuuChina Medical University; China Medical University Beigang Hospital; China Medical University Hospital
- David MischoulonHarvard University; Massachusetts General Hospital
- Jerome J. SarrisThe University of Melbourne; Westmead Institute; Melbourne Clinic; Western Sydney University
- Joseph R. HibbelnNational Institute on Alcohol Abuse and Alcoholism
- Robert K. McNamaraUniversity of Cincinnati Medical Center
- Kei HamazakiUniversity of Toyama
Abstract
Major depressive disorder (MDD) is a complex mental illness with unmet therapeutic needs. The antidepressant effects of ω-3 polyunsaturated fatty acids (n-3 PUFAs) have been widely reported. The subcommittee of the International Society for Nutritional Psychiatry Research organized an expert panel and conducted a literature review and a Delphi process to develop a consensus-based practice guideline for clinical use of n-3 PUFAs in MDD. The guideline focuses on 5 thematic areas: general concepts, acute treatment strategy, depression recurrence monitoring and prevention, use in special populations, and potential safety issues. The key practice guidelines contend that: (1) clinicians and other practitioners are advised to conduct a clinical interview to validate clinical diagnoses, physical conditions, and measurement-based psychopathological assessments in the therapeutic settings when recommending n-3 PUFAs in depression treatment; (2) with respect to formulation and dosage, both pure eicosapentaenoic acid (EPA) or an EPA/docosahexaenoic acid (DHA) combination of a ratio higher than 2 (EPA/DHA >2) are considered effective, and the recommended dosages should be 1-2 g of net EPA daily, from either pure EPA or an EPA/DHA (>2:1) formula; (3) the quality of n-3 PUFAs may affect therapeutic activity; and (4) potential adverse effects, such as gastrointestinal and dermatological conditions, should be monitored, as well as obtaining comprehensive metabolic panels. The expert consensus panel has agreed on using n-3 PUFAs in MDD treatment for pregnant women, children, and the elderly, and prevention in high-risk populations. Personalizing the clinical application of n-3 PUFAs in subgroups of MDD with a low Omega-3 Index or high levels of inflammatory markers might be regarded as areas that deserve future research.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.